GlassScriptPhysician profile
Maria Diana Vornicu
NPI 1689870487
$5,451.57
in general payments reported to CMS, 2019-2025
26 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $259 · 2022: $206 · 2023: $1,538 · 2024: $1,523 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272 · Education: $75.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.95 |
| Education | $75.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $798.94 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $637.73 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $530.11 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Fresenius USA Marketing, INC. | $484.25 | 2019-2025 | Korsuva, Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $380.34 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $358.58 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.36 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $285.28 | 2022-2025 | |
| Vifor Pharma, INC. | $263.11 | 2019-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $247.93 | 2019-2025 | Vafseo, Auryxia |
| Nxstage Medical, INC. | $153.67 | 2019-2025 | Liberty Select Cycler, Nxstage System One |
| Alexion Pharmaceuticals, INC. | $138.15 | 2019-2025 | Ultomiris |
| Ardelyx, INC. | $128.50 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $127.38 | 2019-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $116.10 | 2019-2024 | Rayaldee |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $108.55 | 2022-2025 | Jynarque |
| Horizon Therapeutics Plc | $105.17 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $83.05 | 2025 | |
| Daiichi Sankyo INC. | $57.81 | 2020-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $42.17 | 2023-2024 | Lupkynis |
| Genentech USA, INC. | $23.49 | 2019 | |
| Apellis Pharmaceuticals, INC. | $22.18 | 2025 | Empaveli |
| Boston Scientific Corporation | $20.22 | 2022 | |
| Merck Sharp & Dohme LLC | $18.41 | 2019 | |
| Novo Nordisk INC | $17.57 | 2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Vornicu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.